Rhenium Re 186 etidronate

Drug Profile

Rhenium Re 186 etidronate

Alternative Names: Re 186 HEDP

Latest Information Update: 06 Oct 2004

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mallinckrodt Medical
  • Developer Mallinckrodt Medical; Memorial Sloan-Kettering Cancer Center; University of Cincinnati
  • Class Heavy metals; Non-opioid analgesics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer metastases; Cancer pain

Most Recent Events

  • 06 Oct 2004 Discontinued - Clinical-Phase-Unknown for Cancer metastases in United Kingdom (Injection)
  • 06 Oct 2004 Discontinued - Preregistration for Cancer pain in USA (Injection)
  • 01 Feb 2002 A study has been added to the Pain Control therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top